Abstract: Objective: To study the effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Erlotinib on curative effects and survival rate of non-small cell lung cancer (NSCLC) patients with different mutants of EGFR gene. Methods: 72 cases of advanced NSCLC patients with EGFR positive mutations were divided into study group (n=33) and control group (n=39) according to mutations in exon 19 or 21 of EGFR gene. All the patients were treated with Erlotinib Hydrochloride Tablets orally till disease progression or death. The short-term clinical effective rate, time to progression (TTP) and one-year survival rate of patients in 2 groups were compared. Results: The short-term clinical effective rate, one-year survival rate and average TTP of patients in study group were all obviously higher than control group (P<0.05). Conclusions: The curative effects and survival rate of NSCLC patients with exon 19 mutation were better than NSCLC patients with exon 21 mutation when treating NSCLC with EGFR-TKI Erlotinib. Which suggests that detection of different mutants of EGFR gene may be helpful in formulating individualized therapeutic regimen and predicting the therapeutic effect of EGFR-TKI Erlotinib.

Key words: Non-small cell lung cancer (NSCLC), EGFR gene mutation, Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), Erlotinib

摘要： 目的:研究表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)厄洛替尼对EGFR基因不同突变型非小细胞肺癌(NSCLC)患者疗效及生存率的影响。方法:72例EGFR突变阳性的晚期NSCLC患者,根据EGFR基因第19号外显子或第21号外显子突变分为研究组(33例)和对照组(39例),两组患者均口服盐酸厄洛替尼片至病情进展或因肺癌死亡,比较两组患者近期临床有效率、疾病进展时间(TTP)和1年生存率。结果:研究组近期临床有效率、1年存活率、平均TPP均明显高于对照组,组间比较差异具有统计学意义(P<0.05)。结论:使用EGFR-TKI厄洛替尼治疗NSCLC患者,EGFR第19号外显子突变患者疗效及生存情况均优于EGFR第21号外显子突变患者,提示检测EGFR基因不同突变位点对制定个体化治疗方案及预测EGFR-TKI厄洛替尼的治疗效果有一定的参考作用。

关键词: 非小细胞肺癌（NSCLC）, EGFR基因突变, 表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）, 厄洛替尼